Keyphrases
Abnormal Liver Tests
11%
Acute Hepatitis C
9%
All-cause Mortality
8%
Antiviral Treatment
10%
Barrett's Esophagus
14%
Care Pathway
11%
Chronic Liver Disease
18%
Cirrhosis
43%
Cluster Randomized Trial
10%
Community Pharmacy
15%
Confidence Interval
11%
Cost-effectiveness
10%
Decompensated Cirrhosis
19%
Direct-acting Antiviral Treatment
10%
Direct-acting Antivirals
24%
Drug-induced Liver Injury
10%
Gastroesophageal Reflux Disease
10%
Hazard Ratio
9%
HCV Infection
8%
HCV Treatment
13%
Hepatitis C
100%
Hepatitis C Testing
9%
Hepatitis C Treatment
32%
Hepatitis C Virus
82%
Hepatitis C Virus Infection
38%
Hepatitis C Virus Screening
9%
Hepatocellular Carcinoma
17%
Injection Drug Use
14%
Interferon-free
8%
Liver
25%
Liver Disease
43%
Liver Function Tests
20%
Meta-analysis
9%
Metabolic-associated Fatty Liver Disease (MAFLD)
9%
Non-alcoholic Fatty Liver Disease (NAFLD)
27%
Nonalcoholic Steatohepatitis
12%
Opioid Substitution Treatment
16%
People Who Inject Drugs
56%
Pharmacy
15%
Primary Care
22%
Randomized Controlled Trial
9%
Record Linkage Study
14%
Reinfection
15%
Ribavirin
9%
Risk Factors
12%
Scotland
69%
Scottish
16%
Sustained Viral Response
21%
Sustained Virological Response
20%
Tayside
28%
Medicine and Dentistry
Alcohol Consumption
15%
Antiviral Therapy
23%
Antivirus Agent
11%
Barrett Esophagus
8%
Bleeding
10%
Care Pathway
8%
Chronic Hepatitis C
16%
Chronic Liver Disease
15%
Clinician
5%
Cohort Analysis
9%
Decompensated Liver Cirrhosis
15%
Diagnosis
14%
Disease
15%
Drug Therapy
6%
Drug Use
14%
Fibrosis
16%
Gastroesophageal Reflux
8%
Gene Linkage
20%
Hazard Ratio
10%
Health Care Cost
14%
Hepatitis B
9%
Hepatitis C
95%
Hepatitis C Virus
69%
Hepatitis Virus
7%
Hepatocellular Carcinoma
16%
Hepatology
5%
Human Immunodeficiency Virus
7%
Infection
30%
Interferon
16%
Laparoscopic Surgery
7%
Liver Biopsy
5%
Liver Cirrhosis
47%
Liver Disease
51%
Liver Fibrosis
11%
Liver Function
17%
Liver Function Test
14%
Meta-Analysis
5%
Metabolic Dysfunction-Associated Steatotic Liver Disease
7%
Nonalcoholic Fatty Liver
20%
Patient Referral
8%
Population
6%
Prevalence
11%
Primary Health Care
22%
Public Health
8%
Randomized Controlled Trial
6%
Reinfection
6%
Ribavirin
7%
Secondary Care
6%
Systematic Review
18%
Transjugular Intrahepatic Portosystemic Shunt
7%
